Trial intelligence / Profile preview

Bioequivalence of CHILD-IVITAB vs STROMECTOL in Healthy Adults

NCT05477810Phase 1Completed

Sponsor
University Children's Hospital Basel
Start
Sep 2022
Primary completion
Dec 2022
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, randomised, open-label trial of ivermectin in strongyloidiasis and onchocerciasis (2 arms), sponsored by University Children's Hospital Basel. Primary endpoint: Pharmacokinetics (AUC, Cmax, tmax). Started Sep 2022; status: completed.

02

Drugs

ivermectin
03

Conditions

strongyloidiasisonchocerciasis

Beyond the preview

Go deeper on NCT05477810.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05477810.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call